The Critical Path for Parkinson's Consortium Approach to Developing Consensus Recommendations for Neuroimaging Biomarkers Appropriate for use in Parkinson's Disease Drug Development

被引：0
|
作者：
Muller, M.
Comley, R.
Eberling, J.
Kazmi, H.
Kustermann, T.
Maguire, P.
Marek, K.
McGinnity, C.
Minchik, M.
Parker, C.
Passamonti, L.
Rousset, O.
Russell, D.
Salinas, C.
Seibyl, J.
Sivakumaran, S.
Stoessl, J.
Strafella, A.
Tosun-Turgut, D.
Wang, Y.
Stephenson, D.
Pagano, G.
机构：
来源：
MOVEMENT DISORDERS | 2023年 / 38卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
1590
引用
收藏
页码：S701 / S701
页数：1
相关论文
共 50 条
  • [1] Neuroimaging cerebrovascular biomarkers in Parkinson's disease
    Alves, Mariana
    Lobo, Patricia Pita
    Kauppila, Linda Azevedo
    Rebordao, Leonor
    Cruz, M. Manuela
    Guerreiro, Carla
    Ferro, Jose M.
    Ferreira, Joaquim J.
    Reimao, Sofia
    NEURORADIOLOGY JOURNAL, 2022, 35 (04): : 490 - 496
  • [2] Data Driven Paths to Advancing Precision Medicine Strategies for Parkinson's Disease: Critical Path for Parkinson's Consortium
    Muller, M.
    Dexter, D.
    Cosman, J.
    Zadikoff, C.
    Ali, S.
    Barwick, N.
    Bloem, B.
    Boroojerdi, B.
    Burton, J.
    Carroll, C.
    Cedarbaum, J.
    Dam, T.
    Dawkins, P.
    Grosset, D.
    Hanan, N.
    Hill, D.
    Hu, M.
    Jennings, D.
    Jones, S.
    Kieburtz, K.
    Lawson, R.
    Lee, K.
    Marek, K.
    Matthews, H.
    Mehrotra, N.
    Molinuevo, J.
    Muglia, P.
    Naito, A.
    Pagano, G.
    Sardi, S.
    Schwarzschild, M.
    Simen, A.
    Simuni, T.
    Stebbins, G.
    Venuto, C.
    Williams-Gray, C.
    Stephenson, D.
    MOVEMENT DISORDERS, 2021, 36 : S149 - S150
  • [3] Novel biomarkers and neuroimaging techniques in Parkinson's disease
    Saw, A.
    Bari, S.
    Robertson, Neil P.
    JOURNAL OF NEUROLOGY, 2024, 271 (02) : 1056 - 1058
  • [4] Novel biomarkers and neuroimaging techniques in Parkinson’s disease
    A. Saw
    S. Bari
    Neil P. Robertson
    Journal of Neurology, 2024, 271 : 1056 - 1058
  • [5] Development of Parkinson's disease biomarkers
    Prakash, Kumar M.
    Tan, Eng-King
    EXPERT REVIEW OF NEUROTHERAPEUTICS, 2010, 10 (12) : 1811 - 1825
  • [6] Critical Path for Parkinson's Consortium: Advancing Drug Development Tools and Regulatory Science for PD therapeutic trials
    Romero, K.
    Akalu, M.
    Alexander, R.
    Bloem, B. R.
    Boroojerdi, B.
    Burn, D.
    Cedarbaum, J.
    Conrado, D.
    Dexter, D. T.
    Dorsey, E. R.
    Facheris, M.
    Fischer, T.
    Frasier, M.
    Gallagher, J.
    Gordon, M. Forrest
    Grosset, D.
    Hill, D.
    Ho, C.
    Hu, M. T.
    Kieburtz, K.
    Lassen, A. B.
    Lawson, R.
    Macha, S.
    Marek, K.
    Taylor, K.
    Russell, D.
    Seibyl, J.
    Stafford, B.
    Stebbins, G.
    Venuto, C.
    Williams-Gray, C.
    Yarnall, A.
    Stephenson, D.
    MOVEMENT DISORDERS, 2019, 34 : S17 - S17
  • [7] Advancing regulatory endorsed drug development tools in alignment with emerging biology: The Critical Path for Parkinson's Consortium
    Stephenson, D.
    Kopil, C.
    Mueller, M.
    Mabrouk, O.
    Kocherla, H.
    Comley, R.
    Yee, K.
    Dam, T.
    Pagano, G.
    Seibyl, J.
    Marek, K.
    Simuni, T.
    MOVEMENT DISORDERS, 2024, 39 : S324 - S324
  • [8] Global regulatory agencies support the use of dopamine transporter neuroimaging for subject selection in clinical trials targeting early stage parkinson's disease - on behalf of critical path for Parkinson's (CPP) Consortium
    Stephenson, D.
    Cedarbaum, J.
    Eberling, J.
    Facheris, M.
    Grosset, D.
    Gordon, M.
    Hill, D.
    Imam, S.
    Kern, V.
    Klein, G.
    Matthews, D.
    Muglia, P.
    Roach, A.
    Romero, K.
    Russell, D.
    Seibyl, J.
    Slieker, L.
    Somer, E.
    Sur, C.
    Xie, Z.
    Marek, K.
    MOVEMENT DISORDERS, 2017, 32
  • [9] Assessment of neuroimaging techniques as biomarkers of the progression of Parkinson's disease
    Brooks, DJ
    Frey, KA
    Marek, KL
    Oakes, D
    Paty, D
    Prentice, R
    Shults, CW
    Stoessl, AJ
    EXPERIMENTAL NEUROLOGY, 2003, 184 : S68 - S79
  • [10] Consensus on the use of entacapone in Parkinson's disease
    Obeso, JA
    Burgera, JA
    Castro, A
    Chacón, J
    Roldán, SG
    Grandas, F
    Horga, J
    Kulisevski, J
    Lozano, JJL
    Macías, R
    Marín, C
    Pavón, N
    Díaz, MR
    Oroz, MCR
    Valldeoriola, F
    NEUROLOGIA, 2002, 17 : 77 - 79
12345